ReviewPLoS pathogens2022
Current treatments against mucormycosis and future directions.
Review in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Use of isavuconazole in mucormycosis: a systematic review.BMC infectious diseases · 2025Pooled it
- Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis.Journal of fungi (Basel, Switzerland) · 2026Article
- Surgical therapy for pulmonary aspergillomas and mucormycosis: A 15-year experience from a single clinical center.JTCVS open · 2026Article
- The curious case of aplastic anemia: a fatal triple co-infection with Aspergillus, Mucorales, and Nocardia.BMC infectious diseases · 2026Article
- Leaf mold extract agar facilitates recovery of soil bacterial diversity beyond Bacillus dominance.Applied microbiology and biotechnology · 2026Article
- Repurposing antiviral agents against mucormycosis.PloS one · 2026Article
- Disseminated Mucormycosis with Characteristic Gastric Ulcers and Extensive Intravascular Invasion after ABO-Incompatible Living-Donor Liver Transplantation: A Case Report.Surgical case reports · 2026Article
- Fatal Cutaneous Mucormycosis Initially Misdiagnosed as Necrotizing Fasciitis in an Uncontrolled Diabetic Patient: A Case Report Highlighting Diagnostic Delay.International medical case reports journal · 2026Article
- Pulmonary mucormycosis andAnnals of medicine and surgery (2012) · 2025Article
- Pathogenic mucorales: Deciphering their cell wall polysaccharidome and immunostimulatory potential.Virulence · 2025Article
- Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.Medical mycology · 2025Article
- Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis.BMC microbiology · 2025Article
- Sensitivity and specificity of immunohistochemistry for the diagnosis of filamentous fungal infections.American journal of clinical pathology · 2025Article
- Article
- Rhino-Orbital Mucormycosis With Delayed Diagnosis in an Immunocompromised Patient: A Case Report.Cureus · 2025Article
- Preoperative Administration of Amphotericin B in Orbital Mucormycosis Management: A Case Report.Journal of neurological surgery reports · 2025Article
- Delay in the Diagnosis of Osteoarticular Mucormycosis in Diabetic Ketoacidosis: A Learning Opportunity.Cureus · 2025Article
- Intra-abdominal Mucormycosis in an Immunocompetent Host: A Rare Presentation and Literature Review.Cureus · 2025Article
- The Importance of MRI in the Early Diagnosis of Acute Invasive Fungal Rhinosinusitis.Diagnostics (Basel, Switzerland) · 2025Review
- Appendiceal Perforation and Abdominal Wall Infection Caused by Invasive Mucormycosis in a Child with Acute Leukemia.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mucormycosis (previously called zygomycosis) is a serious but rare fungal infection caused by a group of fungi belonging to the order Mucorales. These molds exist throughout the environment and generally do not cause serious problems in humans. Mucormycosis mainly affects individuals who are immunocompromised. The clinical manifestations of mucormycosis are wide-ranging; they include sinusitis (pansinusitis, rhino-orbital, or rhino-cerebral) as well as cutaneous, gastrointestinal, pulmonary, and disseminate infections. Many uncertainties remain regarding how to control these infections despite the recent addition of triazoles to the antifungal arsenal for treating this infection. Currently, lipid formulations of amphotericin B have become the standard treatment for mucormycosis due to their efficiency. Moreover, a growing body of data supports the need for surgical excision of infected and/or necrosed tissue whenever practical. In this mini review, the current status of treatment options for mucormycosis and recent studies of novel therapeutic options will be presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.